Fig 1: Analysis of ECAD, SPINK1, and their combination to predict PH.(A) ECAD and (B) SPINK1 in plasma of healthy humans with NP (NP; n = 18) compared with patients with ACLD with PH (PH; n = 47) of three different aetiologies: MASH, OH, or HCV. (C) ROC curve of ECAD, SPINK1, and ES and (D) its performance. Data were compared using Student’s t test (*p <0.05). Values of AUROC, the 95% CI, the cut-off value with better Sens and Spec, PPV, and NPV. ACLD, advanced chronic liver disease; AUROC, area under the receiver operating characteristics; ECAD, E-cadherin; ES, ECAD + SPINK1; MASH, metabolic-associated steatohepatitis; NP, normal pressure; NPV, negative predictive value; OH, alcohol-associated; PH, portal hypertension; PPV, positive predictive value; ROC, receiver operating characteristic; Sens, sensitivity; Spec, specificity; SPINK, serine protease inhibitor Kazal-type 1.
Fig 2: Analysis of ECAD, SPINK1, and their combination to predict CSPH.(A) ECAD and (B) SPINK1 in plasma of patients with advanced chronic liver disease with subclinical portal hypertension (HVPG <10; n = 11) or with CSPH (HVPG =10; n = 36) of three different aetiologies: MASH, OH, or HCV. (C) ROC curve of ECAD, SPINK1, and ES and (D) its performance. Data were compared using Student’s t test (*p <0.05). Values of AUROC, the 95% CI, the cut-off value with better Sens and Spec, PPV, and NPV. AUROC, area under the receiver operating characteristics; CSPH, clinically significant portal hypertension; ECAD, E-cadherin; ES, ECAD + SPINK1; HVPG, hepatic venous pressure gradient; MASH, metabolic-associated steatohepatitis; NPV, negative predictive value; OH, alcohol-associated; PPV, positive predictive value; ROC, receiver operating characteristic; Sens, sensitivity; Spec, specificity; SPINK, serine protease inhibitor Kazal-type 1.
Supplier Page from Abcam for Human E-Cadherin ELISA Kit